May 25 (Reuters) - Aroa Biosurgery Ltd (ARX) :
- FY22 PRODUCT SALES GUIDANCE OF $30M-33M
- TOTAL REVENUE FOR FY21 WAS $22.3M
- NORMALISED LOSS BEFORE INCOME TAX FOR FY21 WAS $7.4M
- PRODUCT GROSS MARGINS EXPECTED TO IMPROVE IN H2 FY22
News: ARX Aroa Biosurgery Posts FY22 Product Sales Guidance Of $30M-33M
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
62.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $213.4M | |||
| Open | High | Low | Value | Volume |
| 62.0¢ | 62.5¢ | 62.0¢ | $549.2K | 885.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 46629 | 62.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 63.0¢ | 94400 | 3 |
View Market Depth
| Last trade - 15.37pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
63.0¢ |
Change
0.000 ( 1.61 %) |
||||
| Open | High | Low | Volume | ||
| 62.5¢ | 63.0¢ | 62.0¢ | 164018 | ||
| Last updated 15.55pm 17/06/2024 ? | |||||
| ARX (ASX) Chart |
